Enhabit (EHAB)
Market Price (5/15/2026): $13.8 | Market Cap: $706.6 MilSector: Health Care | Industry: Health Care Facilities
Enhabit (EHAB)
Market Price (5/15/2026): $13.8Market Cap: $706.6 MilSector: Health CareIndustry: Health Care Facilities
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive yieldFCF Yield is 11% Low stock price volatilityVol 12M is 44% Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Geriatric Care, Remote Patient Monitoring, Show more. | Trading close to highsDist 52W High is -2.1%, Dist 3Y High is -4.4% Weak multi-year price returns3Y Excs Rtn is -80% | Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 61% Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 21x Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.1% Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 50% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -4.7% Key risksEHAB key risks include [1] significant financial pressure from proposed Medicare payment cuts and a challenging payer mix shift, Show more. |
| Attractive yieldFCF Yield is 11% |
| Low stock price volatilityVol 12M is 44% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Geriatric Care, Remote Patient Monitoring, Show more. |
| Trading close to highsDist 52W High is -2.1%, Dist 3Y High is -4.4% |
| Weak multi-year price returns3Y Excs Rtn is -80% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 61% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 21x |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is 0.1% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 50% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -4.7% |
| Key risksEHAB key risks include [1] significant financial pressure from proposed Medicare payment cuts and a challenging payer mix shift, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Acquisition by Kinderhook Industries. Enhabit's stock experienced a significant uplift following the announcement on February 23, 2026, that it would be acquired by Kinderhook Industries, LLC in an all-cash transaction for $13.80 per share. This offer represented a premium of approximately 24.4% to Enhabit's closing stock price on February 20, 2026, and a 33.8% premium to the 60-day volume-weighted average share price ending on the same date. The acquisition was unanimously approved by Enhabit's Board of Directors and subsequently by stockholders on May 12, 2026, with the merger expected to close on May 15, 2026.
2. Favorable Litigation Settlement. On February 12, 2026, Enhabit, alongside Encompass Health Corporation, announced the collection of $43.1 million from individual defendants in a Delaware fiduciary breach case. This successful resolution and influx of capital contributed positively to the company's financial standing and investor confidence during the period.
Show more
Stock Movement Drivers
Fundamental Drivers
The 29.8% change in EHAB stock from 1/31/2026 to 5/14/2026 was primarily driven by a 29.0% change in the company's P/S Multiple.| (LTM values as of) | 1312026 | 5142026 | Change |
|---|---|---|---|
| Stock Price ($) | 10.63 | 13.80 | 29.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,048 | 1,065 | 1.6% |
| P/S Multiple | 0.5 | 0.7 | 29.0% |
| Shares Outstanding (Mil) | 51 | 51 | -1.0% |
| Cumulative Contribution | 29.8% |
Market Drivers
1/31/2026 to 5/14/2026| Return | Correlation | |
|---|---|---|
| EHAB | 29.8% | |
| Market (SPY) | 8.4% | -16.4% |
| Sector (XLV) | -4.9% | 17.5% |
Fundamental Drivers
The 69.7% change in EHAB stock from 10/31/2025 to 5/14/2026 was primarily driven by a 67.4% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 5142026 | Change |
|---|---|---|---|
| Stock Price ($) | 8.13 | 13.80 | 69.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,038 | 1,065 | 2.6% |
| P/S Multiple | 0.4 | 0.7 | 67.4% |
| Shares Outstanding (Mil) | 51 | 51 | -1.2% |
| Cumulative Contribution | 69.7% |
Market Drivers
10/31/2025 to 5/14/2026| Return | Correlation | |
|---|---|---|
| EHAB | 69.7% | |
| Market (SPY) | 10.3% | -5.4% |
| Sector (XLV) | 2.5% | 12.5% |
Fundamental Drivers
The 72.7% change in EHAB stock from 4/30/2025 to 5/14/2026 was primarily driven by a 71.2% change in the company's P/S Multiple.| (LTM values as of) | 4302025 | 5142026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.99 | 13.80 | 72.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,035 | 1,065 | 2.9% |
| P/S Multiple | 0.4 | 0.7 | 71.2% |
| Shares Outstanding (Mil) | 50 | 51 | -2.0% |
| Cumulative Contribution | 72.7% |
Market Drivers
4/30/2025 to 5/14/2026| Return | Correlation | |
|---|---|---|
| EHAB | 72.7% | |
| Market (SPY) | 36.5% | 11.0% |
| Sector (XLV) | 6.2% | 6.5% |
Fundamental Drivers
The 12.7% change in EHAB stock from 4/30/2023 to 5/14/2026 was primarily driven by a 16.0% change in the company's P/S Multiple.| (LTM values as of) | 4302023 | 5142026 | Change |
|---|---|---|---|
| Stock Price ($) | 12.25 | 13.80 | 12.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,071 | 1,065 | -0.6% |
| P/S Multiple | 0.6 | 0.7 | 16.0% |
| Shares Outstanding (Mil) | 50 | 51 | -2.3% |
| Cumulative Contribution | 12.7% |
Market Drivers
4/30/2023 to 5/14/2026| Return | Correlation | |
|---|---|---|
| EHAB | 12.7% | |
| Market (SPY) | 86.9% | 20.9% |
| Sector (XLV) | 15.4% | 18.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| EHAB Return | - | -47% | -21% | -25% | 18% | 50% | -45% |
| Peers Return | -20% | -37% | 78% | 35% | 33% | 3% | 66% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 9% | 98% |
Monthly Win Rates [3] | |||||||
| EHAB Win Rate | - | 14% | 33% | 33% | 67% | 80% | |
| Peers Win Rate | 40% | 40% | 55% | 58% | 58% | 48% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| EHAB Max Drawdown | - | - | -55% | -41% | -40% | -7% | |
| Peers Max Drawdown | -47% | -52% | -30% | -25% | -30% | -24% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ADUS, PNTG, AVAH, CHE, BKD.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/14/2026 (YTD)
How Low Can It Go
| Event | EHAB | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -17.6% | -18.8% |
| % Gain to Breakeven | 21.3% | 23.1% |
| Time to Breakeven | 17 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -48.3% | -9.5% |
| % Gain to Breakeven | 93.5% | 10.5% |
| Time to Breakeven | 881 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -24.9% | -6.7% |
| % Gain to Breakeven | 33.1% | 7.1% |
| Time to Breakeven | 51 days | 31 days |
In The Past
Enhabit's stock fell -17.6% during the 2025 US Tariff Shock. Such a loss loss requires a 21.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | EHAB | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -48.3% | -9.5% |
| % Gain to Breakeven | 93.5% | 10.5% |
| Time to Breakeven | 881 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -24.9% | -6.7% |
| % Gain to Breakeven | 33.1% | 7.1% |
| Time to Breakeven | 51 days | 31 days |
In The Past
Enhabit's stock fell -17.6% during the 2025 US Tariff Shock. Such a loss loss requires a 21.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Enhabit (EHAB)
AI Analysis | Feedback
Here are 1-2 brief analogies for Enhabit:
- Enhabit is like 'DoorDash' for comprehensive home health and hospice care.
- Enhabit is like the 'home care division' of a major hospital system such as HCA Healthcare or Mayo Clinic, but operating as a dedicated, standalone company.
AI Analysis | Feedback
- Home Health Services: These services provide in-home medical care, therapy, and support for patients recovering from illness or injury, managing chronic conditions, or needing assistance with daily medical needs.
- Hospice Services: These services offer palliative care, pain and symptom management, and emotional/spiritual support for terminally ill patients and their families.
AI Analysis | Feedback
Major Customers of Enhabit (EHAB)
Enhabit (EHAB) primarily sells its home health and hospice services directly to individuals. The company serves the following categories of customers:
- Individuals requiring home health services: This category includes patients needing skilled nursing care, therapy services (physical, occupational, and speech), wound care, chronic disease management (e.g., diabetes, congestive heart failure, Alzheimer's), post-surgical care, and rehabilitation in their homes.
- Terminally ill individuals: These are patients seeking hospice and palliative care services, which include pain and symptom management, spiritual counseling, and support to meet their physical, emotional, and psychosocial needs at the end of life.
- Families of terminally ill patients: Enhabit also provides support services, such as bereavement counseling, to the families of terminally ill patients, addressing their emotional and psychosocial needs during and after the hospice care period.
AI Analysis | Feedback
nullAI Analysis | Feedback
Barb Jacobsmeyer, President & Chief Executive Officer
Barb Jacobsmeyer has served as President and Chief Executive Officer of Enhabit since June 2021. She is slated to step down from her role on July 31, 2026, or earlier upon the appointment of a successor. Prior to her time at Enhabit, she was Encompass Health's executive vice president of operations, a position she held starting in December 2016. Jacobsmeyer joined Encompass Health in 2007 as CEO of The Rehabilitation Institute of St. Louis. Before joining Encompass Health, she served as CEO for Des Peres Hospital in St. Louis, Missouri. She has over 30 years of experience in healthcare operations and management. Enhabit officially spun off from Encompass Health Corporation on July 1, 2022, with Jacobsmeyer as its President and CEO. During her tenure, she navigated the company through a spinoff, a pandemic, labor challenges, and revised payer and growth strategies.
Ryan Solomon, Chief Financial Officer
Ryan Solomon has served as Chief Financial Officer of Enhabit since December 2024. He brings more than 20 years of corporate strategy and finance experience, including eight years as CFO in the home health and hospice sector and other industries. Before joining Enhabit, Solomon was the CFO of Aspirion, a technology-enabled healthcare revenue cycle management provider. Prior to Aspirion, he served as CFO of AccentCare, a national leader in home health, hospice, and personal care services, from February 2020 to October 2023. Earlier in his career, Solomon held roles in finance and strategic planning at Apple Leisure Group, where he ultimately served as CFO from January 2018 to February 2020. He also held finance positions at Alcon Laboratories and American Airlines.
Julie Jolley, Executive Vice President, Home Health
Julie Jolley has been with Enhabit since January 2000 and currently serves as Executive Vice President of Home Health.
Jeanne Kalvaitis, Executive Vice President, Hospice
Jeanne Kalvaitis has served as Enhabit's Executive Vice President of Hospice since June 2022. She has over 30 years of healthcare administrative experience. Before joining Enhabit, she was Vice President Hospice Operations and Divisional Vice President Clinical Services for Compassus from 2019 to 2021, where she was involved in the transition of Ascension at Home hospice agencies following their acquisition by Compassus. Kalvaitis also served as Enhabit's Vice President of Clinical Services from 2014 to 2019 and held various positions at Vitas Healthcare Corporation from 1990 to 2014.
Dylan Black, General Counsel and Secretary
Dylan Black has served as General Counsel and Secretary of Enhabit since January 2023. Prior to that, he was a partner at the law firm Bradley Arant Boult Cummings LLP in Birmingham, Alabama, where he practiced from 1998 to 2022. Before his private practice career, Black clerked for the Hon. Harry W. Wellford on the U.S. Court of Appeals for the Sixth Circuit in Memphis, Tennessee.
AI Analysis | Feedback
Enhabit (EHAB) faces several significant risks to its business operations and financial performance. The most prominent current risk stems from the proposed acquisition of Enhabit by Kinderhook Industries. There is a risk that the proposed transaction may not be completed in a timely manner or at all, which could adversely affect Enhabit's business and the price of its common stock. This includes the potential failure to satisfy conditions such as regulatory approvals and stockholder consent, or the occurrence of any event that could cause the deal to fall through, potentially leading to operational disruption. Secondly, Enhabit is exposed to substantial reimbursement and regulatory risks. A significant portion of the company's revenue is derived from Medicare and Medicaid, making it vulnerable to potential regulatory changes in Medicare payment models and ongoing rate headwinds. Proposed payment cuts, such as those related to future Medicare payment rules, could negatively impact Enhabit's revenue and profitability. Lastly, Enhabit faces ongoing labor and workforce challenges. The company has consistently encountered staffing shortages, an increased reliance on contract staff, and rising market rates for nurses and other healthcare professionals. These challenges directly impact Enhabit's capacity to serve patient volumes and control costs in its home health and hospice segments.AI Analysis | Feedback
The increasing adoption and expansion of "hospital-at-home" models by large health systems represent a clear emerging threat. These models leverage technology and in-person visits to deliver acute care services, traditionally provided in hospitals, directly within a patient's home. If major health systems significantly expand their direct provision of such comprehensive home-based acute care, including skilled nursing, therapy, and medical management, they could internalize services that would otherwise be referred to independent home health agencies like Enhabit. This shift could lead to increased competition for higher-acuity patient populations and potentially reduce Enhabit's market share and referral opportunities for its home health services.
AI Analysis | Feedback
Enhabit (EHAB) operates in the significant U.S. home health and hospice markets. The U.S. home healthcare market was estimated at approximately $162.35 billion in 2024. Projections indicate this market is expected to reach around $222.61 billion in 2025. For hospice services, the U.S. hospice market was valued at approximately $29.92 billion in 2024. This market is projected to grow to an estimated $31.21 billion in 2025.AI Analysis | Feedback
Enhabit, Inc. (EHAB) is poised for future revenue growth over the next 2-3 years, driven by several strategic initiatives focusing on expansion, payer optimization, and volume increases across its home health and hospice segments.
Here are 5 expected drivers of future revenue growth for Enhabit:
- De Novo Development, with a Focus on Hospice Services: Enhabit is actively expanding its footprint by opening new branches, particularly prioritizing hospice service locations. The company aims to establish approximately 10 new de novo sites annually, with a strategic 60/40 split favoring hospice openings, often co-located near existing home health operations to leverage brand recognition and referral networks. For example, Enhabit opened one new hospice branch in Q1 2025, with 13 additional de novo projects underway.
- Strategic Acquisitions, Emphasizing Hospice: The company is pursuing targeted small to medium-sized mergers and acquisitions, with an 80/20 bias towards hospice acquisitions to strengthen its market presence and diversify revenue streams. This approach allows for cost-effective market entry and complements existing operations.
- Payer Innovation and Contract Optimization: Enhabit is dedicated to refining its payer innovation strategy, which includes renegotiating contracts for improved pricing and increasing non-Medicare patient volumes. The finalization of a significant national contract with UnitedHealthcare in December 2024, for instance, restored Enhabit's position as a full-service provider, enabling it to better leverage its referral network. As of late 2024, 48% of home health non-Medicare visits were under improved-rate payer innovation contracts.
- Growth in Hospice Average Daily Census (ADC) and Admissions: The hospice segment is a significant growth driver, showing robust performance. Enhabit anticipates hospice average daily census (ADC) growth between 7% to 8.5% during 2025. In Q1 2025, hospice revenue surged 20.5% year-over-year, and hospice ADC increased by 12.3%. The company's case management model implemented in 2023 continues to mature, contributing to sustained hospice ADC increases.
- Stabilization and Growth in Home Health Non-Medicare Admissions: While navigating market conditions for home health, Enhabit is focusing on stabilizing Medicare admissions and driving growth in non-Medicare admissions. Home health non-Medicare admissions increased by 7.4% year-over-year in Q1 2025. The new national contract secured in December 2024 is expected to position Enhabit for continued growth in its home health segment into 2025 by allowing it to operate as a full-service provider to referral sources.
AI Analysis | Feedback
Share Issuance
- Enhabit, Inc. commenced trading as an independent public company under the symbol EHAB on the New York Stock Exchange in July 2022, following its separation from Encompass Health.
Inbound Investments
- In February 2026, Enhabit announced a definitive agreement to be acquired by Kinderhook Industries, LLC, a private equity firm, for $13.80 per share in cash, totaling approximately $1.1 billion in enterprise value. The acquisition is projected to close in the second quarter of 2026.
Outbound Investments
- In 2025, Enhabit opened a total of 10 de novo locations.
- In April 2024, the company opened one new home health de novo location in Florida.
- Since 2015, Enhabit has deployed over $798 million in 42 home health and hospice acquisitions and established 44 de novo locations across 21 states.
Capital Expenditures
- Capital expenditures for property and equipment amounted to $3.5 million in 2023 and $3.8 million in 2024.
- These expenditures are primarily focused on computer hardware and licensing software, in addition to leasehold improvements.
- Enhabit anticipates approximately $5 million in maintenance capital expenditures for 2025.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Enhabit Earnings Notes | 12/16/2025 | |
| With Enhabit Stock Surging, Have You Considered The Downside? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to EHAB.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 25.35 |
| Mkt Cap | 1.6 |
| Rev LTM | 1,941 |
| Op Inc LTM | 126 |
| FCF LTM | 100 |
| FCF 3Y Avg | 53 |
| CFO LTM | 135 |
| CFO 3Y Avg | 92 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 11.4% |
| Rev Chg 3Y Avg | 8.3% |
| Rev Chg Q | 4.8% |
| QoQ Delta Rev Chg LTM | 1.1% |
| Op Inc Chg LTM | 43.4% |
| Op Inc Chg 3Y Avg | 30.9% |
| Op Mgn LTM | 8.5% |
| Op Mgn 3Y Avg | 6.6% |
| QoQ Delta Op Mgn LTM | 0.3% |
| CFO/Rev LTM | 7.6% |
| CFO/Rev 3Y Avg | 5.7% |
| FCF/Rev LTM | 6.3% |
| FCF/Rev 3Y Avg | 4.1% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 1.6 |
| P/S | 1.1 |
| P/Op Inc | 14.7 |
| P/EBIT | 18.9 |
| P/E | 11.9 |
| P/CFO | 12.8 |
| Total Yield | 3.6% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 4.4% |
| D/E | 0.5 |
| Net D/E | 0.5 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 5.7% |
| 3M Rtn | -6.5% |
| 6M Rtn | 11.8% |
| 12M Rtn | 26.9% |
| 3Y Rtn | 108.5% |
| 1M Excs Rtn | -1.1% |
| 3M Excs Rtn | -16.3% |
| 6M Excs Rtn | 3.1% |
| 12M Excs Rtn | -0.7% |
| 3Y Excs Rtn | 36.2% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Home Health | 825 | 850 | 877 | 897 | 878 |
| Hospice | 210 | 196 | 194 | 209 | 201 |
| Total | 1,035 | 1,046 | 1,071 | 1,107 | 1,078 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Home Health | 159 | 169 | |||
| Hospice | 42 | 36 | |||
| Net income attributable to noncontrolling interests | 2 | 2 | |||
| Stock-based compensation expense | -12 | -9 | |||
| Depreciation and amortization | -32 | -31 | |||
| Non-segment general and administrative expenses | -113 | -129 | |||
| Impairment of goodwill | -162 | -86 | |||
| Total | -115 | -47 |
Price Behavior
| Market Price | $13.80 | |
| Market Cap ($ Bil) | 0.7 | |
| First Trading Date | 06/23/2022 | |
| Distance from 52W High | -2.1% | |
| 50 Days | 200 Days | |
| DMA Price | $13.76 | $10.26 |
| DMA Trend | up | up |
| Distance from DMA | 0.3% | 34.4% |
| 3M | 1YR | |
| Volatility | 46.2% | 44.6% |
| Downside Capture | -143.32 | -6.83 |
| Upside Capture | -14.93 | 26.66 |
| Correlation (SPY) | -16.9% | 9.6% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.02 | -0.05 | -0.51 | -0.11 | 0.44 | 0.72 |
| Up Beta | 0.05 | 0.04 | 0.11 | 0.32 | 0.81 | 0.63 |
| Down Beta | -0.12 | 0.25 | -0.34 | 0.38 | 0.54 | 0.80 |
| Up Capture | -15% | -10% | -9% | 21% | 47% | 39% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 7 | 17 | 31 | 63 | 128 | 371 |
| Down Capture | -0% | -23% | -193% | -148% | -10% | 95% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 7 | 13 | 19 | 48 | 107 | 349 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with EHAB | |
|---|---|---|---|---|
| EHAB | 39.0% | 44.3% | 0.87 | - |
| Sector ETF (XLV) | 13.2% | 15.0% | 0.62 | 8.6% |
| Equity (SPY) | 29.1% | 12.0% | 1.83 | 8.7% |
| Gold (GLD) | 42.9% | 26.8% | 1.30 | 1.7% |
| Commodities (DBC) | 44.5% | 18.5% | 1.84 | -4.5% |
| Real Estate (VNQ) | 12.1% | 13.4% | 0.60 | 10.5% |
| Bitcoin (BTCUSD) | -23.7% | 41.7% | -0.54 | 1.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with EHAB | |
|---|---|---|---|---|
| EHAB | -8.8% | 53.8% | -0.03 | - |
| Sector ETF (XLV) | 5.1% | 14.6% | 0.17 | 18.7% |
| Equity (SPY) | 13.7% | 17.1% | 0.63 | 20.4% |
| Gold (GLD) | 20.0% | 17.9% | 0.91 | 1.8% |
| Commodities (DBC) | 10.7% | 19.4% | 0.44 | 9.3% |
| Real Estate (VNQ) | 3.2% | 18.8% | 0.07 | 22.3% |
| Bitcoin (BTCUSD) | 6.8% | 55.9% | 0.33 | 6.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with EHAB | |
|---|---|---|---|---|
| EHAB | -4.5% | 53.8% | -0.03 | - |
| Sector ETF (XLV) | 9.6% | 16.5% | 0.47 | 18.7% |
| Equity (SPY) | 15.7% | 17.9% | 0.75 | 20.4% |
| Gold (GLD) | 13.4% | 15.9% | 0.69 | 1.8% |
| Commodities (DBC) | 8.3% | 17.9% | 0.38 | 9.3% |
| Real Estate (VNQ) | 5.3% | 20.7% | 0.22 | 22.3% |
| Bitcoin (BTCUSD) | 67.9% | 66.9% | 1.07 | 6.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/5/2026 | 0.0% | -0.1% | 2.6% |
| 11/5/2025 | -6.1% | -1.9% | 13.9% |
| 8/6/2025 | 15.2% | 11.8% | 15.1% |
| 3/5/2025 | -6.1% | 0.0% | -0.4% |
| 11/6/2024 | 0.1% | -3.8% | -2.3% |
| 7/15/2024 | -3.1% | 0.1% | -13.8% |
| 3/6/2024 | 22.1% | 37.9% | 40.2% |
| 11/7/2023 | 16.0% | 14.2% | 28.9% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 5 | 5 | 6 |
| # Negative | 8 | 8 | 7 |
| Median Positive | 15.2% | 11.8% | 14.5% |
| Median Negative | -7.0% | -5.2% | -9.0% |
| Max Positive | 22.1% | 37.9% | 40.2% |
| Max Negative | -18.2% | -24.8% | -15.4% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 03/05/2026 | 10-K |
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 03/06/2025 | 10-K |
| 09/30/2024 | 11/08/2024 | 10-Q |
| 06/30/2024 | 08/08/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 03/15/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/12/2023 | 10-Q |
| 12/31/2022 | 04/14/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/12/2022 | 10-Q |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | McQuiddy, Collin | Chief Accounting Officer | Direct | Sell | 3112026 | 13.61 | 1,403 | 19,095 | 54,318 | Form |
| 2 | Jolley, Julie Diane | EVP of Home Health Operations | Direct | Sell | 3112026 | 13.63 | 2,793 | 38,069 | 1,869,082 | Form |
| 3 | Jolley, Julie Diane | EVP of Home Health Operations | Direct | Sell | 3112026 | 13.63 | 2,793 | 38,069 | 1,907,150 | Form |
| 4 | Solomon, Ryan | Chief Financial Officer | Direct | Buy | 8112025 | 7.64 | 10,000 | 76,400 | 1,478,096 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.